Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

Biochemical Pharmacology

Volumn 78, Issue 8, 2009, Pages 1008-1016

  Kerr, Barry D ^a   Irwin, Nigel ^a   O'Harte, Finbarr P M ^a   Bailey, Clifford J ^b   Flatt, Peter R ^a   Gault, Victor A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Dipeptidylpeptidase IV (DPP IV); GIP agonist; Glucose homeostasis; Glucose dependent insulinotropic polypeptide (GIP); Insulin secretion

Indexed keywords

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE(37 LYSINE MYRISTIC ACID); GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE(37 LYSINE PALMITIC ACID); GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE(37 LYSINE STEARIC ACID); INSULIN; N ACYLGLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; N ACYLGLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE(37 LYSINE MYRISTIC ACID); N ACYLGLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE(37 LYSINE PALMITIC ACID); N ACYLGLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE[37 LYSINE STEARIC ACID]; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; FATTY ACIDS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE TOLERANCE TEST; HALF-LIFE; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, OBESE; TIME FACTORS;

EID: 69349096792     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.037     Document Type: Article

References (24)

1. Brown J.C. Enteroinsular axis. In: Dockray G.J., and Walsh J.H. (Eds). Gut peptides: biochemistry and physiology (1994), Raven Press, New York 765-784
2. Holst J.J., Vilsbøll T., and Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297 (2009) 127-136
3. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109 (2001) 288-303
4. Irwin N., Flatt P.R., and Gault V.A. GIP-based therapeutics for diabetes and obesity. Curr Chem Biol 2 (2008) 61-68
5. Vilsbøll T., Knop F.K., Krarup T., Johansen A., Madsbad S., Laren S., et al. The pathophysiology of diabetes involves a defective amplification of late phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88 (2003) 4897-4903
6. Nauck M.A., Heimesaat M.M., Ørskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
7. Piteau S., Oliver A., Kim S.J., Winter K., Pospisilik J.A., Lynn F., et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycaemia in Zucker rat. Biochem Biophys Res Commun 362 (2007) 1007-1012
8. Aaboe K., Knop F.K., Vilsbøll T., Madsbad S., Deacon C.F., Holst J.J., et al. Acute administration of a sulfonylurea compound restores the insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 50 S1 (2007) S248 [Abstract]
9. Green B.D., Irwin N., Gault V.A., O'Harte F.P.M., and Flatt P.R. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vas Dis 5 (2005) 134-140
10. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependant insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
11. Meier J.J., Nauck M.A., Kranz D., Holst J.J., Deacon C.F., Gaeckler D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 (2004) 654-662
12. Flatt P.R., Green B.D., and Bailey C.J. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 13 (2008) 3648-3660
13. Gault V.A., Kerr B.D., Irwin N., and Flatt P.R. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem Pharmacol 75 (2008) 2325-2333
14. Irwin N., Green B.D., Gault V.A., Greer B., Harriott P., Bailey C.J., et al. Degradation, insulin secretion and antihyperglycemic actions of two palmitate-dervitized N-terminal proglutamyl analogues of glucose dependent insulinotropic polypeptide. J Med Chem 48 (2005) 1244-1250
15. Irwin N., Green B.D., Mooney M.H., Greer B., Harriott P., Bailey C.J., et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther 314 (2005) 1187-1194
16. 37). Biol Chem 386 (2005) 679-687
17. Irwin N., O'Harte F.P.M., Gault V.A., Green B.D., Greer B., Harriott P., et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem 49 (2006) 1047-1054
18. Irwin N., Clarke G.C., Green B.D., Greer B., Harriott P., Gault V.A., et al. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol 72 (2006) 719-728
19. Vilsbøll T., Brock B., Perrild H., Levin K., Lervang H.H., Kølendorf K., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetes Med 25 (2008) 152-156
20. Bailey C.J., and Flatt P.R. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 6 (1982) 11-21
21. Fields G.B., and Noble R.L. Solid-phase peptide synthesis utilizing 9-florenylmethoxycarbonyl amino acids. Int J Pept Prot Res 35 (1990) 161-214
22. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P.M., Yoon T.W., et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electro-fusion. Diabetes 45 (1996) 1132-1140
23. Stevens J.F. Determination of glucose by an automated analyser. Clin Chem Acta 32 (1971) 199-201
24. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20 (1981) 573-577